141 related articles for article (PubMed ID: 35529288)
1. Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement.
Karbhari N; Lara-Martinez H; Hill JM
Case Rep Oncol; 2022; 15(1):345-350. PubMed ID: 35529288
[TBL] [Abstract][Full Text] [Related]
2. Refractory Chronic Lymphocytic Leukemia with Central Nervous System Involvement: A Case Report with Literature Review.
Nakanishi T; Ito T; Fujita S; Satake A; Konishi A; Hotta M; Yoshimura H; Nomura S
J Blood Med; 2020; 11():487-502. PubMed ID: 33380856
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
4. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
5. Unusual Relapse of Chronic Lymphocytic Leukemia After Remission.
Rizvi W; Truong Q
Cureus; 2018 Feb; 10(2):e2176. PubMed ID: 29651369
[TBL] [Abstract][Full Text] [Related]
6. Can Treatment with Venetoclax for Chronic Lymphocytic Leukemia (CLL) Result In Autoimmune Hemolytic Anemia?
Abdel-Samad N; Sughayar R
Am J Case Rep; 2021 Mar; 22():e928514. PubMed ID: 33750754
[TBL] [Abstract][Full Text] [Related]
7. Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
Svanberg R; Ostrowski SR; Nasserinejad K; Kersting S; Dobber JA; Mattson M; Tran HTT; Levin MD; Mous R; Kater AP; Niemann CU
Leuk Lymphoma; 2020 Dec; 61(14):3422-3431. PubMed ID: 32865439
[TBL] [Abstract][Full Text] [Related]
8. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Yi X; Jain N; Iles LR; Ayres ML; Wierda WG; Gandhi V
Front Oncol; 2022; 12():833714. PubMed ID: 35273915
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.
Tang X; Zou W; Peng P; Bai Y
Clin Exp Med; 2022 May; 22(2):161-171. PubMed ID: 34224006
[TBL] [Abstract][Full Text] [Related]
10. Chronic Lymphocytic Leukaemia: Rare Involvement of the Central Nervous System.
Amado C; Duarte V; Silva Leal M; Cruz M; Ferreira G
Eur J Case Rep Intern Med; 2021; 8(11):002847. PubMed ID: 34912734
[TBL] [Abstract][Full Text] [Related]
11. A case report of the metagenomics next-generation sequencing for early detection of central nervous system mucormycosis with successful rescue in patient with recurrent chronic lymphocytic leukemia.
Zhang J; Luo J; Weng X; Zhu Y; Goyal G; Perna F; Espinoza-Gutarra M; Jiang L; Chen L; Mi JQ
Ann Transl Med; 2022 Jun; 10(12):722. PubMed ID: 35845522
[TBL] [Abstract][Full Text] [Related]
12. Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Viswanathan K; Roboz G; Chadburn A; Mathew S
Int J Surg Pathol; 2020 Apr; 28(2):216-224. PubMed ID: 31544558
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report.
Zhang X; Chen J; Wang W; Li X; Tan Y; Zhang X; Qian W
Front Oncol; 2021; 11():693670. PubMed ID: 34290987
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategy in chronic lymphocytic leukemia with symptomatic central nervous system involvement: A case report.
Dewaide R; Saevels K
Clin Case Rep; 2023 Nov; 11(11):e7965. PubMed ID: 37953895
[TBL] [Abstract][Full Text] [Related]
15. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
16. Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax.
Rogers KA; Emond B; Manceur AM; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
Curr Med Res Opin; 2021 Aug; 37(8):1409-1420. PubMed ID: 34003049
[TBL] [Abstract][Full Text] [Related]
17. Hearing Loss due to Infiltration of the Tympanic Membrane by Chronic Lymphocytic Leukemia.
Cohen JB; Cavaliere R; Byrd JC; Andritsos LA
Case Rep Hematol; 2012; 2012():589718. PubMed ID: 23198191
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs.
Vitale C; Montalbano MC; Salvetti C; Boccellato E; Griggio V; Boccadoro M; Coscia M
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31979293
[TBL] [Abstract][Full Text] [Related]
19. Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review.
Albakr A; Alhothali W; Samghabadi P; Maeda L; Nagpal S; Ajlan A
Cureus; 2018 Nov; 10(11):e3660. PubMed ID: 30755837
[TBL] [Abstract][Full Text] [Related]
20. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
